| Today’s Big NewsJun 12, 2024 |
| By Annalee Armstrong Pfizer and Flagship Pioneering have settled on the first target for their billion-dollar, multiprogram collaboration and it’s not exactly a surprise: The New York pharma giant will work with the venture creation firm’s ProFound Therapeutics to develop new obesity drugs. |
|
|
|
By Nick Paul Taylor Foresite Capital CEO Jim Tananbaum says we’re in “one of the best biotech investment environments” of his multi-decade career—and has rounded up $900 million to put that belief to the test with a fresh set of big bets. |
By Gabrielle Masson Amid an organizational reset, Bayer’s SVP and Global Head of Biotech Jens Vogel, Ph.D., has hit the exits after four years with the German pharma. |
Sponsored by Montgomery County Economic Development Corporation Drive or take the metro in any direction within Montgomery County, Maryland, and you'll come across a life science company responsible for a major innovation. |
|
Tuesday, June 25, 2024 | 11am ET / 8am PT Expanded Access Programs can help deliver life-saving access to critical medications. Join us for a deep dive into the benefits of EAPs in Europe. Learn how to leverage for achieving faster access to the European market, facilitating successful commercialization, and navigating the array of regulations and guidelines. Register now.
|
|
By Nick Paul Taylor Ultragenyx and Mereo BioPharma have broken off another piece of brittle bone data, linking their drug candidate to sustained reductions in fracture rates in a midphase clinical trial. |
By James Waldron An early readout from a study in humans with obesity has again demonstrated the drug’s anti-inflammatory potential. |
By Gabrielle Masson Avidity Biosciences’ AOC 1020, newly dubbed del-brax, demonstrated a safe profile and was tied to functional improvement among people with facioscapulohumeral muscular dystrophy in a phase 1/2 trial. |
By Annalee Armstrong GSK and Ochre Bio will work together in a $37.5 million partnership to pinpoint the drivers of liver disease. |
By Gabrielle Masson,Annalee Armstrong,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Nick Paul Taylor Eli Lilly looks set to make the long-deserted Alzheimer’s disease market a two-horse town—but that may be a good thing for Biogen and Eisai. William Blair analysts are tipping the anticipated approval of a rival anti-amyloid therapy to boost Leqembi by helping raise awareness, although they also see possible risks to the early frontrunner after Lilly waltzed through its advisory committee. |
By Helen Floersh IQVIA hopes to help clinical trial sites rein in the number of different software systems they have to manage with a new platform that puts them all behind a single dashboard, potentially improving their capacity for studies. |
By Conor Hale Shortly after announcing positive clinical trial data from its pulsed field ablation treatment for irregular heart rhythms, Kardium has more good news to share. |
By Helen Floersh Lokavant has released a new artificial intelligence solution that it claims can help contract research organizations and sponsors predict, optimize and control clinical trials in real time. |
By Kevin Dunleavy Sen. Bernie Sanders is stepping up his attack on Novo Nordisk over the prices the company charges in the U.S. for its wildly popular diabetes and weight loss drugs. Sanders, the chairman of the Senate Committee on Health, Education, Labor and Pensions, is asking the committee to vote on whether it should subpoena Novo’s North American operations chief Doug Langa to face questions at a hearing on July 10. |
Fierce podcastsDon’t miss an episode |
| In this week’s episode of “The Top Line,” the Fierce Pharma Marketing team discusses the annual top pharma drug ad spenders special report. |
|
|---|
|
|
|
July 8-9, 2024 | Jersey City, NJ Hear the latest industry trends from leaders in the field, and developed with input from our esteemed advisory board, to ensure you have a sound plan for your company, brands, and yourself.
Save $200 when you Register Today!
|
|
| WebinarWatch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
| WhitepaperNew molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
| WhitepaperThis detailed case study shows how Fresenius Medical Care achieved 25 times faster insights to help kidney disease patients, launching the world’s largest global database of dialysis care with fully anonymized patient data. Sponsored by: Privacy Analytics, an IQVIA company |
| WhitepaperThis paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
